Free tool
FAERS Monitor: Odefsey
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208351 or its brand name (Odefsey, Emtricitabine, Rilpivirine Hydrochloride, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.
Reports
3,596
Serious
2,736
76% of reports
Hospitalization
390
Death reported
72
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bone density decreased1,605
- chronic kidney disease874
- tooth loss822
- osteoporosis758
- bone loss748
- osteonecrosis713
- pain711
- emotional distress692
- multiple fractures691
- renal failure650
- anxiety645
- anhedonia604
- osteopenia539
- renal injury524
- skeletal injury462
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 52 |
| 2017 | 119 |
| 2018 | 224 |
| 2019 | 379 |
| 2020 | 1,378 |
| 2021 | 542 |
| 2022 | 342 |
| 2023 | 176 |
| 2024 | 183 |
| 2025 | 143 |
| 2026 | 58 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bone density decreasedSignal | 1,605 | 315.7 | 303.9 | 478,155 |
| bone lossSignal | 748 | 306.2 | 286.7 | 216,100 |
| skeletal injurySignal | 462 | 273.5 | 250.6 | 119,616 |
| multiple fracturesSignal | 691 | 256.8 | 239.7 | 168,543 |
| tooth lossSignal | 822 | 241.4 | 227.0 | 188,954 |
| osteopeniaSignal | 539 | 215.4 | 198.9 | 110,796 |
| anhedoniaSignal | 604 | 137.6 | 127.8 | 79,970 |
| osteonecrosisSignal | 713 | 129.8 | 121.4 | 89,135 |
| osteoporosisSignal | 758 | 109.8 | 103.0 | 80,261 |
| renal injurySignal | 524 | 105.0 | 96.9 | 52,991 |
| chronic kidney diseaseSignal | 874 | 68.1 | 64.2 | 57,218 |
| emotional distressSignal | 692 | 33.6 | 31.4 | 21,869 |
| renal failureSignal | 650 | 28.8 | 26.8 | 17,417 |
| anxietySignal | 645 | 13.3 | 12.4 | 7,398 |
| painSignal | 711 | 6.8 | 6.3 | 3,596 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.